{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:38:38Z","timestamp":1791362318589,"version":"4.3.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"national cancer institute","doi-asserted-by":"publisher","award":["K08CA252619"],"award-info":[{"award-number":["K08CA252619"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00262-021-03033-z","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:04:15Z","timestamp":1629453855000},"page":"807-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-618X","authenticated-orcid":false,"given":"Jennifer A.","family":"Lenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles-Antoine","family":"Assenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Louka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Keuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9830-3151","authenticated-orcid":false,"given":"Matthew J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"1","key":"3033_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.53.1","volume":"53","author":"E Takahashi","year":"2013","unstructured":"Takahashi E, Nakamura S (2013) Histiocytic sarcoma\u202f: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53(1):1\u20138","journal-title":"J Clin Exp Hematop"},{"issue":"2","key":"3033_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2017-10-812495","volume":"131","author":"A Kommalapati","year":"2018","unstructured":"Kommalapati A, Tella SH, Durkin M, Go RS, Goyal G (2018) Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood 131(2):265\u20138","journal-title":"Blood"},{"issue":"9","key":"3033_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","volume":"28","author":"JL Hornick","year":"2004","unstructured":"Hornick JL, Jaffe ES, Fletcher CDM (2004) Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 28(9):1133\u20131144","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"3033_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2559.2002.01418.x","volume":"41","author":"SA Pileri","year":"2002","unstructured":"Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JKC et al (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41(1):1\u201329","journal-title":"Histopathology"},{"issue":"1","key":"3033_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ejh.12755","volume":"97","author":"J Ansari","year":"2016","unstructured":"Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD et al (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97(1):9\u201316","journal-title":"Eur J Haematol"},{"issue":"5","key":"3033_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12185-014-1630-y","volume":"100","author":"H Tsujimura","year":"2014","unstructured":"Tsujimura H, Miyaki T, Yamada S, Sugawara T, Ise M, Iwata S et al (2014) Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation. Int J Hematol 100(5):507\u2013510","journal-title":"Int J Hematol"},{"issue":"20","key":"3033_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMc1511490","volume":"378","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Solit DB, Tap WD (2018) Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation. N Engl J Med 378(20):1945\u20131947","journal-title":"N Engl J Med"},{"key":"3033_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vetimm.2015.11.003","volume":"169","author":"MJ Atherton","year":"2016","unstructured":"Atherton MJ, Morris JS, McDermott MR, Lichty BD (2016) Cancer immunology and canine malignant melanoma: a comparative review. Vet Immunol Immunopathol 169:15\u201326","journal-title":"Vet Immunol Immunopathol"},{"issue":"324","key":"3033_CR9","doi-asserted-by":"publisher","first-page":"324ps5","DOI":"10.1126\/scitranslmed.aaf0746","volume":"8","author":"AK LeBlanc","year":"2016","unstructured":"LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL et al (2016) Perspectives from man\u2019s best friend: National Academy of Medicine\u2019s Workshop on Comparative Oncology. Sci Transl Med 8(324):324ps5-324ps5","journal-title":"Sci Transl Med"},{"key":"3033_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/vco.12595","volume":"18","author":"MJ Atherton","year":"2020","unstructured":"Atherton MJ, Lenz JA, Mason NJ (2020) Sarcomas - a barren immunological wasteland or field of opportunity for immunotherapy? Vet Comp Oncol 18:447\u2013470","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"3033_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1354\/vp.39-1-74","volume":"39","author":"VK Affolter","year":"2002","unstructured":"Affolter VK, Moore PF (2002) Localized and Disseminated Histiocytic Sarcoma of Dendritic Cell Origin in Dogs. Vet Pathol 39(1):74\u201383","journal-title":"Vet Pathol"},{"issue":"8","key":"3033_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/jsap.12688","volume":"58","author":"JA Lenz","year":"2017","unstructured":"Lenz JA, Furrow E, Craig LE, Cannon CM (2017) Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition? J Small Anim Pract 58(8):461\u2013467","journal-title":"J Small Anim Pract"},{"issue":"Suppl 1","key":"3033_CR13","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1093\/jhered\/esp039","volume":"100","author":"J Abadie","year":"2009","unstructured":"Abadie J, H\u00e9dan B, Cadieu E, De Brito C, Devauchelle P, Bourgain C et al (2009) Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. J Hered 100(Suppl 1):S19-27","journal-title":"J Hered"},{"issue":"2","key":"3033_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1476-5829.2008.00181.x","volume":"7","author":"J Dobson","year":"2009","unstructured":"Dobson J, Hoather T, McKinley TJ, Wood JLN (2009) Mortality in a cohort of flat-coated retrievers in the UK. Vet Comp Oncol 7(2):115\u2013121","journal-title":"Vet Comp Oncol"},{"issue":"10","key":"3033_CR15","first-page":"1041","volume":"48","author":"AK Fulmer","year":"2007","unstructured":"Fulmer AK, Mauldin GE (2007) Canine histiocytic neoplasia: An overview. Can Vet J 48(10):1041\u20131050","journal-title":"Can Vet J"},{"key":"3033_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2018.01.012","volume":"188","author":"DL Gustafson","year":"2018","unstructured":"Gustafson DL, Duval DL, Regan DP, Thamm DH (2018) Canine sarcomas as a surrogate for the human disease. Pharmacol Ther 188:80\u201396","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3033_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","volume":"21","author":"KA Skorupski","year":"2007","unstructured":"Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS et al (2007) CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 21(1):121\u2013126","journal-title":"J Vet Intern Med"},{"issue":"2","key":"3033_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1476-5829.2009.00186.x","volume":"7","author":"KA Skorupski","year":"2009","unstructured":"Skorupski KA, Rodriguez CO, Krick EL, Clifford CA, Ward R, Kent MS (2009) Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy*. Vet Comp Oncol 7(2):139\u2013144","journal-title":"Vet Comp Oncol"},{"issue":"11","key":"3033_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1471-2407-11-201","volume":"26","author":"B Hedan","year":"2011","unstructured":"Hedan B, Thomas R, Motsinger-Reif A, Abadie J, Andre C, Cullen J et al (2011) Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer 26(11):201","journal-title":"BMC Cancer"},{"issue":"6","key":"3033_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/ijc.32991","volume":"147","author":"B H\u00e9dan","year":"2020","unstructured":"H\u00e9dan B, Rault M, Abadie J, Ulv\u00e9 R, Botherel N, Devauchelle P et al (2020) PTPN11 mutations in canine and human disseminated histiocytic sarcoma. Int J Cancer 147(6):1657\u20131665","journal-title":"Int J Cancer"},{"issue":"11","key":"3033_CR21","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1158\/1535-7163.MCT-17-1273","volume":"17","author":"M Takada","year":"2018","unstructured":"Takada M, Hix JML, Corner S, Schall PZ, Kiupel M, Yuzbasiyan-Gurkan V (2018) Targeting MEK in a translational model of histiocytic sarcoma. Mol Cancer Ther 17(11):2439\u20132450","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"3033_CR22","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-019-02360-6","volume":"68","author":"L Tarone","year":"2019","unstructured":"Tarone L, Barutello G, Iussich S, Giacobino D, Quaglino E, Buracco P et al (2019) Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. Cancer Immunol Immunother 68(11):1839\u20131853","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"3033_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, Levine BL, June CH (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16(9):566\u2013581","journal-title":"Nat Rev Cancer"},{"issue":"5795","key":"3033_CR24","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960\u20131964","journal-title":"Science"},{"issue":"4","key":"3033_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298\u2013306","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3033_CR26","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.5858\/arpa.2018-0220-RA","volume":"142","author":"SL Skala","year":"2018","unstructured":"Skala SL, Lucas DR, Dewar R (2018) Histiocytic sarcoma: review, discussion of transformation from B-cell lymphoma, and differential diagnosis. Arch Pathol Lab Med 142(11):1322\u20131329","journal-title":"Arch Pathol Lab Med"},{"key":"3033_CR27","doi-asserted-by":"crossref","unstructured":"Picarsic JL, Chikwava K (2018) Foundations in diagnostic pathology, hematopathology. 3rd edn, Disorders of Histiocytes, Elsevier, pp 567\u2013616.e4","DOI":"10.1016\/B978-0-323-47913-4.00019-7"},{"key":"3033_CR28","doi-asserted-by":"crossref","unstructured":"Miranda RN, Medeiros LJ (2018) Diagnostic pathology: lymph nodes and extranodal lymphomas. 2nd edn, Histiocytic Sarcoma, Elsevier, pp 812\u2013821","DOI":"10.1016\/B978-0-323-47779-6.50110-1"},{"issue":"1","key":"3033_CR29","doi-asserted-by":"publisher","first-page":"e27491","DOI":"10.1002\/pbc.27491","volume":"66","author":"S Bose","year":"2019","unstructured":"Bose S, Robles J, McCall CM, Lagoo AS, Wechsler DS, Schooler GR et al (2019) Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma. Pediatr Blood Cancer. 66(1):e27491","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"3033_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450\u2013461","journal-title":"Cancer Cell"},{"issue":"19","key":"3033_CR31","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064\u20135074","journal-title":"Clin Cancer Res"},{"issue":"23","key":"3033_CR32","doi-asserted-by":"publisher","first-page":"19819","DOI":"10.18632\/oncotarget.4378","volume":"6","author":"Z Gatalica","year":"2015","unstructured":"Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ et al (2015) Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget 6(23):19819\u201319825","journal-title":"Oncotarget"},{"issue":"4","key":"3033_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/0300985817690208","volume":"54","author":"A Marcinowska","year":"2017","unstructured":"Marcinowska A, Constantino-Casas F, Williams T, Hoather T, Blacklaws B, Dobson J (2017) T lymphocytes in histiocytic sarcomas of flat-coated retriever dogs. Vet Pathol 54(4):605\u2013610","journal-title":"Vet Pathol"},{"issue":"2\u20133","key":"3033_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jcpa.2012.06.009","volume":"148","author":"Y Kato","year":"2013","unstructured":"Kato Y, Murakami M, Hoshino Y, Mori T, Maruo K, Hirata A et al (2013) The class A macrophage scavenger receptor CD204 is a useful immunohistochemical marker of canine histiocytic sarcoma. J Comp Pathol 148(2\u20133):188\u2013196","journal-title":"J Comp Pathol"},{"issue":"4","key":"3033_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jcpa.2014.07.003","volume":"151","author":"F Pierezan","year":"2014","unstructured":"Pierezan F, Mansell J, Ambrus A, Rodrigues HA (2014) Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats. J Comp Pathol 151(4):347\u2013351","journal-title":"J Comp Pathol"},{"issue":"11","key":"3033_CR36","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1158\/0008-5472.CAN-17-0084","volume":"77","author":"JP Frazier","year":"2017","unstructured":"Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO et al (2017) Multidrug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. Cancer Res 77(11):2869\u20132880","journal-title":"Cancer Res"},{"issue":"22","key":"3033_CR37","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao L, Anel A, Pardo J (2015) How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 21(22):5047\u20135056","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3033_CR38","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","volume":"72","author":"A Facciabene","year":"2012","unstructured":"Facciabene A, Motz GT, Coukos G (2012) T regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72(9):2162\u20132171","journal-title":"Cancer Res"},{"issue":"5","key":"3033_CR39","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"14","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang S, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 14(5):15179","journal-title":"Sci Rep"},{"issue":"6230","key":"3033_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74\u201380","journal-title":"Science"},{"issue":"2","key":"3033_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh D, Holl\u00fd J, Yewdell JW (2021) A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol 21(2):116\u2013128","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3033_CR42","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1172\/JCI90962","volume":"127","author":"V Afshar-Kharghan","year":"2017","unstructured":"Afshar-Kharghan V (2017) The role of the complement system in cancer. J Clin Invest 127(3):780\u2013789","journal-title":"J Clin Invest"},{"issue":"1","key":"3033_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X et al (2018) Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer. 17(1):129","journal-title":"Mol Cancer."},{"issue":"12","key":"3033_CR44","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542\u2013e551","journal-title":"Lancet Oncol"},{"issue":"4","key":"3033_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","volume":"40","author":"J Xu","year":"2016","unstructured":"Xu J, Sun HH, Fletcher CDM, Hornick JL, Morgan EA, Freeman GJ et al (2016) Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders. Am J Surg Pathol 40(4):443\u2013453","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"3033_CR46","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/vco.12197","volume":"15","author":"G Hartley","year":"2017","unstructured":"Hartley G, Faulhaber E, Caldwell A, Coy J, Kurihara J, Guth A et al (2017) Immune regulation of canine tumour and macrophage PD-L1 expression. Vet Comp Oncol 15(2):534\u2013549","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"3033_CR47","doi-asserted-by":"publisher","first-page":"e0150030","DOI":"10.1371\/journal.pone.0150030","volume":"11","author":"M Tagawa","year":"2016","unstructured":"Tagawa M, Maekawa N, Konnai S, Takagi S (2016) Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma. PLoS ONE. 11(2):e0150030","journal-title":"PLoS ONE."},{"issue":"2","key":"3033_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","volume":"232","author":"J Galon","year":"2014","unstructured":"Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C et al (2014) Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours. J Pathol 232(2):199\u2013209","journal-title":"J Pathol"},{"issue":"1","key":"3033_CR49","doi-asserted-by":"publisher","first-page":"1676615","DOI":"10.1080\/2162402X.2019.1676615","volume":"9","author":"MK Panjwani","year":"2020","unstructured":"Panjwani MK, Atherton MJ, MaloneyHuss MA, Haran KP, Xiong A, Gupta M et al (2020) Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology 9(1):1676615","journal-title":"Oncoimmunology"},{"key":"3033_CR50","volume":"10","author":"S Dow","year":"2019","unstructured":"Dow S (2019) A role for dogs in advancing cancer immunotherapy research. Front Immunol 10:","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03033-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03033-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T01:12:11Z","timestamp":1650244331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03033-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03033-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}